Medical Advisory Council

Donna Culton, MD, PhD
Chapel Hill, NC
University of North Carolina- Chapel Hill

Ron Feldman, MD, PhD
Atlanta, GA
Emory University

Tanya Gibson, DDS
Kansas City, MO
University of Missouri- Kansas City

Robert Kelsch, DMD
New York, NY
Long Island Jewish Medical Center, Hofstra North Shore-LIJ School of Medicine

M. Peter Marinkovich, MD
Stanford, CA
Stanford University

Yoshiyuki Mochida, DDS, PhD
Boston, MA
Boston University

Angela Ritchie, DDS
Omaha, NE
University of Creighton

Animesh A. Sinha, MD, PhD
Buffalo, NY
State University of New York – Buffalo

Mary Tomayko, MD, PhD
New Haven, CT
Yale University

Annette Czernik, MD
New York, NY
Mount Sinai Dermatology

David Fivenson, MD
Ann Arbor, MI
Fivenson Dermatology 

Sergei Grando, MD, PhD, DSc
Irvine, CA
University of California-Irvine

Joel M. Laudenbach, DMD
Charlotte, NC
Atrium Health

Emanual Maverakis, MD
Sacramento, CA
UC Davis Health

Aimee Payne, MD, PhD
Philadelphia, PA
University of Pennsylvania

Nasser Said-Al-Naief, DDS, MS
Portland, OR
Oregon Health & Science University

Thomas Sollecito, DMD, FDS, RCSEd
Philadelphia, PA
Penn Medicine

Victoria Werth, MD
Philadelphia, PA
University of Pennsylvania

IPPF Corporate Council

In 2020, the IPPF launched the Corporate Council, a collection of top stake-holders that are committed to facilitating collaboration and information exchange among patients, the IPPF, key opinion leaders, health-related organizations, and industry. We believe that only through an open and cooperative collaboration among all stakeholders will we effectively be able to address issues facing the pemphigus and pemphigoid (P/P) community.

The IPPF Corporate Council focuses on three areas of emphasis: access, advocacy, and awareness. Within these focus areas, the IPPF Corporate Council develops and supports activities and programs that ensure the IPPF fulfills its mission of improving the quality of life for all people affected by P/P through early diagnosis and support.

Membership in the IPPF Corporate Council demonstrates an organization’s leadership and commitment to addressing the challenges facing our patients. Involvement in the Council also provides the IPPF with an extended network of expertise and insight to ensure that we continue to address the unmet needs of all patients.

The Corporate Council provides hope and support by:

  • Enhancing awareness, knowledge, and attention of P/P in society and among key audiences
  • Organizing the IPPF community to drive progress in advocacy, awareness, research, drug development, and access to care
  • Encouraging an industry, academic, and community collaborative investment in, and development of, new/improved treatments and therapies
  • Promoting more effective identification, diagnosis, and treatment of P/P to improve patient experience/outcomes

IPPF Corporate Council Members